Loading clinical trials...

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)

NCT01885208•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Locations (146)

Novo Nordisk Investigational Site

Anniston, Alabama, United States

Novo Nordisk Investigational Site

Birmingham, Alabama, United States

Novo Nordisk Investigational Site

Pell City, Alabama, United States

Novo Nordisk Investigational Site

Glendale, Arizona, United States

Novo Nordisk Investigational Site

Mesa, Arizona, United States

Novo Nordisk Investigational Site

Phoenix, Arizona, United States

Novo Nordisk Investigational Site

Burbank, California, United States

Novo Nordisk Investigational Site

Hawaiian Gardens, California, United States

Novo Nordisk Investigational Site

Lomita, California, United States

Novo Nordisk Investigational Site

Los Angeles, California, United States

Key Dates

Start Date

December 2, 2013

Primary Completion Date

July 13, 2015

Completion Date

July 13, 2015

Last Updated

June 13, 2019

Enrollment

813

ACTUAL participants

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

semaglutide

DRUG

exenatide

DRUG

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions